Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Starts Phase I Trial of Subcutaneous ATTR Drug

Premium

Alnylam Pharmaceuticals this week announced that it has started a phase I trial of its subcutaneous TTR-mediated amyloidosis treatment ALN-TTRsc.

The study is being conducted in the UK and will examine single and multiple escalating doses of the drug in up to 40 healthy volunteers.

The trial’s primary endpoints are safety and tolerability, and secondary objectives include assessment of clinical activity as measured by serum levels of the TTR protein. Data is expected to be available by mid-year, Alnylam said.

As previously disclosed, a phase II trial of ALN-TTRsc is slated to begin before the end of 2013, with a pivotal trial on track for 2014.

The Scan

Guidelines for Ancient DNA Work

More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature.

And Cleared

A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times.

Suit Over Allegations

The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director.

Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants

In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.